Celcuity, Inc.

Industry

  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Cytology
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Technologies
See more in Biomedtracker

Latest on Celcuity, Inc.

Pink Sheet

Keeping Track: US FDA Clears New Uses For Incyte’s Pemazyre, AbbVie’s Imbruvica; Minerva Seeks First Negative Symptoms Claim In Schizophrenia

 
• By Bridget Silverman

The dog days of summer were apparent in the slow pace of news, but the US FDA’s oncology and hematology reviewers put out two approval letters, granting a pediatric graft versus host disease indicatio

Scrip

Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers

 
• By Joseph Haas, John Davis, and Anju Ghangurde

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Collaborates With Artios On DD

Scrip

Pfizer Triples Down On CDK Inhibition In Breast, Other Cancers

 
• By Mandy Jackson

Pfizer Inc. is moving forward quickly with clinical development of three new CDK inhibitors to build on its Ibrance (palbociclib) breast cancer franchise – at a time when sales of competing CDK4/6 in

In Vivo

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

 
• By Maureen Riordan and Amanda Micklus

Device Transactions Device fundraising in Q4 2017 totaled $2.6 billion, the highest single-quarter value of the year. However, total 2017 financing for the industry declined from 2016: $8.4 billion in